

Max Taubert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1881033/publications.pdf>

Version: 2024-02-01

26
papers

377
citations

932766

10
h-index

794141

19
g-index

26
all docs

26
docs citations

26
times ranked

626
citing authors

#	ARTICLE	IF	CITATIONS
1	The relation between tau pathology and granulovacuolar degeneration of neurons. <i>Neurobiology of Disease</i> , 2021, 147, 105138.	2.1	9
2	Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2342-2351.	1.3	1
3	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. <i>BMC Cancer</i> , 2021, 21, 719.	1.1	10
4	A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1240-1249.	2.3	2
5	Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1495-1508.	1.6	9
6	A Population Pharmacokinetic Model of (R)- and (S)- Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 961-971.	1.0	5
7	Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function. <i>Scientific Reports</i> , 2021, 11, 22656.	1.6	2
8	A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2020, 59, 781-808.	1.6	42
9	Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. <i>Scientific Reports</i> , 2020, 10, 12457.	1.6	12
10	The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. <i>Journal of Intensive Care</i> , 2020, 8, 86.	1.3	37
11	A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1237-1253.	1.0	4
12	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	1.3	14
13	Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 711-722.	1.1	10
14	Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics. <i>Neurocritical Care</i> , 2020, 33, 740-748.	1.2	9
15	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1398-1407.	2.3	19
16	A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 518.	1.6	7
17	A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 1097-1106.	1.4	5
18	Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 682-690.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and Pâ€Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1249-1259.	2.3	18
20	Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 611-618.	0.8	5
21	Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	3
22	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. <i>Thrombosis Journal</i> , 2018, 16, 28.	0.9	63
23	Using a three-compartment model improves the estimation of iohexol clearance to assess glomerular filtration rate. <i>Scientific Reports</i> , 2018, 8, 17723.	1.6	16
24	Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2304-2310.	1.3	25
25	Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	3
26	Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5254-5261.	1.4	39